ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

TNXP Stock Forecast: 12-month Price Target of $2.63 (Updated March 2022)

TNXP Stock Forecast And Price Prediction (Updated March 2022)

TNXP stock has a 12-month price target of $2.63. Ten analysts set the price prediction considering the latest three-month stock price, the market capitalization of $122.80 million, and its PE ratio of -0.88. TNXP stock forecast, however, the price of TNXP shares can vary between US$ 2.25 and US$ 3.00. The stock is trading at $0.23 per stock and is projected to rise by 143.47%.

tnxp stock forecast renevue estimate

Why TNXP Stock Forecast Is Bullish

 TNXP Stock Forecast
Source: Getty Images

TNXP stock has risen by almost 4 percent today and has increased by more than 20% in the past month. Tonix made the most important announcement on March 21st as the company announced the results of its Phase 3 RALLY Study on TNX102 SL 5.6m for managing Fibromyalgia.

“The outstanding result of RELIEF research is in stark contrast to the RALLY missed the main endpoint. The discrepancy in these research results may be due to a 79 percent rise in adverse event-related participant abandonments in the medication treatment program in RALLY compared with RELIEF. Similar results were reported for the placebo group…”. A 77 percent increase was observed in adverse event-related participant withdrawals.” Dr. Gregory Sullivan CMO at Tonix Pharmaceuticals said.

Although the research is still far from being completed, the data is encouraging to say the least. But, of course, it is up to you to decide if this data makes TNXP one of the best stocks to buy now.

TNXP Forecast Rises After Orphan Drug Designation

TNXP Stock Forecast Rises After
Source: Getty Images

Tonix announced that the FDA had made its drug TNX-2900 to treat and prevent Prader-Willi disease an orphan drug (FDA).

These benefits include exemption from user fees and tax credits and the possibility of market exclusivity for “seven years” after approval. That is a big win for investors and a positive step forward.

The FDA will usually approve the drug if it has a high chance of success. The FDA may grant exclusive status to the TNX-2900. However, you can also expedite the clearance process using your symbolic seal.

Current studies show that Tonix has an unmet medical need. They also have positive results. Investors are optimistic about the company’s prospects, as evidenced by today’s price movements in TNXP stock.

The drug was eligible for FDA orphan drug status and is intended to help more than 200,000 people in the United States. This status allows TNXP to have seven years of exclusive use.

According to a statement from Tonix, Seth Lederman, CEO of Tonix, said, “That was a significant milestone and one that justified our efforts to assess the value of TNX-2900 in the treatment of Prader Willi syndrome.”

The pharmaceutical and biotechnology sectors highly value certification. In addition, these drugs are financially more profitable than traditional pharmaceuticals because of their lower development costs and high-profit margins.

TNXP Stock Forecast After Fourth-Quarter Results

TNXP stock fourth-quarter results
Source: Getty Images

State Street Corp. raised Tonix Pharmaceuticals’ stock price by 6% in the first three months of this year. State Street Corp. purchased 5,020,193 more shares in the last quarter. That brings its total stake to 5,097.793 shares. Its value is $5,659,000. BlackRock Inc. increased its Tonix Pharmaceuticals holdings by 3.1 percent during the third quarter.

BlackRock Inc. stock has increased its acquisition by 820,552, adding 27,321,653 shares afterward with a total investment equivalent to $16,422,000. Parametric Portfolio Associates LLC bought Tonix Pharmaceuticals in the second quarter spending approximately $72,000 in shares. In addition, the California State Teachers Retirement System bought Tonix Pharmaceuticals in the second quarter spending roughly $500,000.

Lastly, SG Americas Securities LLC increased its Tonix Pharmaceuticals holdings by 1,670.2% in the third quarter. SG Americas Securities LLC purchased an additional 216,640 shares of company stock. That brings the total to 229,611. Institutional investors and hedge funds own 17.46% of the stock.

Tonix Pharmaceuticals Company Overview

TNXP
Source: Getty Images

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has developed an innovative new treatment for Fibromyalgia. The treatment is called Fibrosine, and it is being offered as a generic alternative to other products on the market.

Tonix Pharmaceuticals has taken significant steps to develop this treatment, including working with scientists. TNXP has found a way to make the molecule available to sufferers in a generic form, raising concerns about its safety. Nevertheless, the team has developed an effective and affordable medication.

In recent years, there has been a growing trend of people looking for more information about molecules that have the potential to help with Fibromyalgia. That is partly because many of these molecules are not yet known to the general population.

Fibromyalgia is a condition that affects the connective tissue in the body. It’s caused by a disorder called rheumatoid arthritis, and it causes inflammation in the body. To find out what’s causing Fibromyalgia, researchers have been looking into a molecule called cyclobenzaprine.

However, there is currently no cure for Fibromyalgia, so it’s essential to find a medication to help manage the condition. Unfortunately, there are many different types of fibromyalgia medications, and it can be hard to find one that is available in your area. That’s where Tonix Pharmaceuticals comes in.

 

The post TNXP Stock Forecast: 12-month Price Target of $2.63 (Updated March 2022) appeared first on Best Stocks.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.